...
首页> 外文期刊>Frontiers in neuroendocrinology >Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes
【24h】

Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes

机译:当前药物疗法对2型糖尿病患者认知障碍的潜在影响

获取原文
获取原文并翻译 | 示例
           

摘要

Type 2 diabetes mellitus is a complex metabolic disease that can cause serious damage to various organs. Among the best-known complications, an important role is played by cognitive impairment. Impairment of cognitive functioning has been reported both in type 1 and 2 diabetes mellitus. While this comorbidity has long been known, no major advances have been achieved in clinical research; it is clear that appropriate control of blood glucose levels represents the best current (although unsatisfactory) approach in the prevention of cognitive impairment. We have focused our attention on the possible effect on the brain of antidiabetic drugs, despite their effects on blood glucose levels, giving a brief rationale on the mechanisms (e.g. GLP-1, BDNF, ghrelin) that might be involved. Indeed, GLP-1 agonists are currently clinically studied in other neurodegenerative diseases (i.e. Parkinson's and Alzheimer's disease); furthermore, also other antidiabetic drugs have proven efficacy in preclinical studies. Overall, promising results are already available and finding new intervention strategies represents a current need in this field of research. (C) 2016 Elsevier Inc. All rights reserved.
机译:2型糖尿病是一种复杂的代谢疾病,可能会严重损害各个器官。在最著名的并发症中,认知障碍发挥着重要作用。在1型和2型糖尿病中都报告了认知功能受损。尽管这种合并症早已为人所知,但在临床研究中尚未取得重大进展。显然,适当地控制血糖水平代表了预防认知障碍的最佳方法(尽管不能令人满意)。尽管抗糖尿病药对血糖水平有影响,但我们仍将注意力集中在其对大脑的可能影响上,并简要说明了可能涉及的机制(例如GLP-1,BDNF,ghrelin)。确实,目前在其他神经退行性疾病(例如帕金森氏症和阿尔茨海默氏病)中对GLP-1激动剂进行了临床研究。此外,在临床前研究中还证明了其他抗糖尿病药的功效。总体而言,已经有了可喜的结果,寻找新的干预策略代表了该研究领域的当前需求。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号